Category Archives: Immunotherapy for Cancer

Alternative Cancer Treatment, Breast Cancer, Cancer Care Tips, Cancer Research, Cancer Survivors, Immunotherapy, Immunotherapy for Cancer, News

Higher Vitamin D Levels May Boost Breast Cancer Survival

Higher Vitamin D Levels May Boost Breast Cancer Survival
Higher Vitamin D Levels May Boost Breast Cancer Survival

Vitamin D has long been known as an essential nutrient that aids your bones with calcium absorption. A recent study shows that there may also be a link between vitamin D levels and surviving breast cancer.

Examining the Link between Vitamin D and Breast Cancer Survival

The study, performed by a research team from the Roswell Park Cancer Institute in Buffalo, began in 2006 with a group of women from California who had been diagnosed with invasive breast cancer. Participants were divided into three sub-groups based on blood levels of a particular vitamin D marker.

Women with more advanced cancers tended to have low levels of the marker. Over an average of seven years of follow-up, 100 of these women died compared to 76 women with high levels. There were approximately 1,600 women total involved in the study.

In addition, women with the highest vitamin D levels were 28 percent less likely to die of any cause, once factors such as tumor characteristics were accounted for. This link was the strongest among pre-menopausal women.

What Does This Mean for the Future?

According to lead author Song Yao, overall results showed “30 percent reduction of all-cause mortality” linked to vitamin D levels at the time of diagnosis. While the study supports previous research linking vitamin D with breast cancer survival, Yao said a randomized controlled trial would be needed to determine a direct cause-and-effect.

Immunotherapy for Cancer: Going Beyond Traditional Treatments

Immunotherapy for cancer has been gaining a lot of attention recently, but at Issels® we have a decades-long history of using these state-of-the-art methods successfully. Contact us for more information.

Alternative Cancer Treatment, Immunotherapy, Immunotherapy for Cancer

Rare Cancers Still Plague Vietnam Veterans

Get The Treatment You Need
Get The Treatment You Need

More than 40 years after the end of the Vietnam War, the conflict continues to have both physical and emotional effects on those who served. Several vets are fighting a rare form of cancer that stems from food they ingested overseas.

When Food Becomes Deadly

Residents of Vietnam and other parts of Asia have long known about the dangers of eating raw or poorly cooked river fish. It often holds parasites known as liver flukes that latch onto the lining of the bile duct, causing inflammation and scarring over time.

Decades later, the afflicted patient can develop a rare cancer called cholangiocarcinoma. Sadly, the symptoms usually don’t present themselves until the later stages after the tumor has advanced.

Vietnam Vets Struggle for Assistance

According to Ralph Erickson, head of post-deployment health services for the Department of Veteran Affairs, roughly 700 cholangiocarcinoma patients have gone through the agency’s medical system. However, less than half of them submitted claims because it never occurred to them that the cancer was linked to their military service.

Michael Baughman, a 64-year-old veteran from Danville, VA, is one of the patients who was diagnosed with bile duct cancer. He acknowledged the bitter irony that he survived combat but is likely to die due to eating a fish.

Immunotherapy for Cancer Offers Hope to Many Patients

Today immunotherapy for cancer is regarded as the most advanced of current treatments. Our individually tailored non-toxic protocols may be used alone or in conjunction with more traditional methods. Contact us to learn why Issels® is the leader in state-of-the-art immunotherapy for cancer.

Alternative Cancer Treatment, Immuno-Oncology, Immunotherapy, Immunotherapy for Cancer

The Issels Story – a Focus on Immunotherapy

2 Comments
Another Step in Stopping Cancer
We Are Dedicated to Stopping Cancer

Immunotherapy for cancer has been a hot topic in the news lately, but the methods are far from new. Our founder, Dr. Josef Issels, was a pioneer in the field of integrative immuno-oncology dating back to the mid-20th century.

Josef Issels: A Life Dedicated to Fighting Cancer

Dr. Issels began his trailblazing path in 1948, conducting extensive research on the causes of cancer while working in his native Germany. His studies focused on the role of the immune system in fighting cancer as well as microbial aspects of the disease.

In 1951, Dr. Issels founded the first hospital in the world devoted exclusively to integrative immunotherapy, focusing on patients for whom traditional treatments had failed. The revolutionary Issels program went above and beyond standard tumor-centered treatments, and many patients experienced partial or total long-term remission.

As the integrative procedures developed by Dr. Issels continued to generate successful results, the hospital added 35 beds in 1970 for a total of 125. The scope of research also expanded to include programs such as vaccines, hypothermia and mycoplasma.

After Dr. Issels retired, he brought his innovative immuno-oncology programs to America. Since his death in 1998, his wife, Ilse Marie, has continued his work alongside their sons, Christian and Hellmut. The trio has maintained the same dedication and level of excellence set forth by Dr. Issels.

Issels® Continues to Lead the Way in Immunotherapy for Cancer

Nearly 70 years later, our patients continue to benefit from the foresight and tireless work of Josef Issels. Contact us for more information about our state-of-the-art programs that are personally tailored to meet each patient’s specific needs.

Cancer Research, Immuno-Oncology, Immunotherapy for Cancer

Genetic Advances Made in Prostate Cancer Identification

Prostate cancer affects approximately 15 percent of males in their lifetime, and is second only to skin cancer. Recent identification of an overactive gene that accelerates prostate cancer could lead to development of a more effective treatment.

Prostate Cancer Evolves Beyond Drugs

Most prostate tumors are caused by a form of cancer called adenocarcinoma. In advanced stages, adenocarcinoma is treated with drugs that block androgens, the male hormones that fuel the tumor. Unfortunately, the tumors have evolved into a more aggressive, androgen-resistant form called neuroendocrine prostate cancer.

Prostate Cancer Identification
Prostate Cancer Identification

A cross-disciplinary team supported by the Prostate Cancer Foundation discovered a gene known as N-Myc that appears to be the driver behind the change to the more aggressive form. While N-Myc is not usually found in prostate cancer, it has been known to occur in other forms such as neuroblastoma, a rare cancer of the nervous system found in children.

A Pathway to New Treatment Methods

When N-Myc goes into overdrive, it teams up with a protein called EZH2 to block the tumor’s androgen signaling and “flips the switch” on the molecular program that leads to the more aggressive neuroendocrine form. Dr. Jonathan W. Simons, president and CEO of the Prostate Cancer Foundation, calls this a “game-changing” discovery that can enable development of more successful treatments.

Personalized, Non-Toxic Treatments for Prostate Cancer

Issels® offers a wide range of Immunotherapy for Cancer protocols, including vaccines and NK cells that have been used to treat patients with prostate cancer, melanoma, leukemia and all other forms. Contact us today to find out how Immunotherapy for Cancer at Issels® can help you or your loved one.

Cancer Care Tips, Cancer Research, Immunotherapy, Immunotherapy for Cancer

Does Treatment Cause Cancer to Spread?

Can Cancer Treatment Causer The Spread of Cancer
Can Cancer Treatment Causer The Spread of Cancer

One of the obstacles to immunotherapy for cancer and other traditional treatments is that the disease can reoccur. While it was believed this was due to cancer cells developing resistance to drugs, recent evidence suggests that the problem may be the treatments themselves.

“A Double-Edged Sword”

Penicillin and other antibiotics were once hailed as “wonder drugs,” but overuse resulted in many forms of bacteria adapting and becoming immune to the toxic effects. The medical community felt the same process was behind the tendency of cancer to reoccur and spread to other areas.

A recent discovery by a team of Israeli scientists has shed new light on the problem. Their study involved mice with multiple myeloma, which is produced in bone marrow and spreads throughout the body. They received treatment with bortezomib, an anti-cancer drug with the brand name of Velcade.

The researchers were surprised to find that Velcade caused inflammatory cells in the bone marrow to accelerate the cancer, arming the cells with resistant properties. While they emphasize that “treatment with Velcade is essential and necessary,” the team is working on methods to inhibit the body’s response so treatments are more effective.

Immunotherapy for Cancer: A Personalized Approach

Our Issels® immunotherapy treatments are developed to meet each patient’s individual needs. These integrative programs attack cancer cells directly and treat the underlying causes to reduce the risk of tumor growth and reoccurrence.

Contact us to learn more about cancer vaccines, NK cells and the other non-toxic immunotherapy for cancer treatments offered at Issels®.

Cancer Research, Immunotherapy, Immunotherapy for Cancer, News

Immunotherapy is the Hot Buzz in the World of Cancer Research Publications

Could Immunotherapy Be Your Miracle Treatment?
Cancer Immunothereapy in the News

Thanks to rapid and effective developments, immunotherapy for cancer continues to be a hot topic in the medical community. A recent analysis shows the explosive growth of this subject in academic and industrial publications.

Immunotherapy for Cancer in the News

Results of the analysis conducted by Drs. Enal Razvi and Gary Oosta were published in Genetic Engineering & Biotechnology News. Data was based on publications in the broad space of cancer immunology, which have seen exponential growth from zero in the early ’70s to more than 600 in the past year.

While there has been a clear increase in quantity, what about qualitative measures? A word cloud corresponding to titles and abstracts shows that the major areas of focus are “cancer,” “immunotherapy,” “cells,” “immune” and “tumor.”

Drilling down to find the key components of these publications, the most commonly mentioned one is “dendritic cells,” which play a vital role in initiating the immune response. “Cell death” (apoptosis) has generated 33 percent annual growth.

What Does the Future Hold?

Drs. Razvi and Oosta drew the following conclusions:

  • Understanding in vivo mechanisms and pathways driving immunological cascades is crucial for continued progress.
  • Companies will continue clinical trials, both individually and in collaboration with others.
  • Immunotherapy for cancer will eventually use biomarkers to identify which populations and sub-populations are the optimum candidates for specific treatments.

Individualized Blueprints for Immunotherapy

At Issels®, our integrative therapies are personalized based on each patient’s lifestyle and genetic makeup as well as the tumor microenvironment. Contact us today to hear success stories from patients of all ages who have dealt with leukemia, melanoma and other forms of cancer.